Frank Jaksch, Jr. Biography and Net Worth

Director of Niagen Bioscience

Frank L. Jaksch Jr. serves as the Co-Founder and Chairman of the Board of Niagen Bioscience. As a pioneer in the natural products chemistry, ingredient development and bioscience industries, Mr. Jaksch founded the company in 1999 and has been instrumental in its evolution from a natural products chemical and service provider to a global leader in NAD+ science and commercialization.

Mr. Jaksch served as the company's Chief Executive Officer from its founding until June 2018, when he transitioned to the role of Executive Chairman to focus on strategic initiatives and scientific innovation. Under his leadership, the company successfully licensed key patents for nicotinamide riboside (Niagen®) in starting in 2009, developed the commercial production process that established Niagen as the leading NAD+ precursor in the market and in 2016 listed the company on Nasdaq.

Throughout his tenure, Mr. Jaksch has overseen research, strategy, and operations with a particular emphasis on scientific advancement and novel product development for pharmaceutical and nutraceutical applications. His vision and scientific background have been central to the company's ingredient development strategy, research collaborations with leading academic institutions and the development of its intellectual property portfolio.

Prior to founding the company, Mr. Jaksch served as International Subsidiaries Manager at Phenomenex, a life science analytical chemistry company, where he managed international subsidiary operations and business development from 1992 to 1999.

Beyond his role at Niagen Bioscience, Mr. Jaksch is the Chairman and CEO of Ayana Bio, a company focused on developing plant cell-derived bioactive ingredients for health and wellness applications. He also serves on several scientific advisory boards and industry associations focused on advancing nutraceutical science and industry standards.

Mr. Jaksch holds a Bachelor of Science degree in Chemistry and Biology from Valparaiso University.

What is Frank L. Jaksch, Jr.'s net worth?: The estimated net worth of Frank L. Jaksch, Jr. is at least $1.64 million as of December 13th, 2024. Mr. Jaksch, Jr. owns 244,179 shares of Niagen Bioscience stock worth more than $1,635,999 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Jaksch, Jr. may own. Learn More about Frank L. Jaksch, Jr.'s net worth.
How do I contact Frank L. Jaksch, Jr.?: The corporate mailing address for Mr. Jaksch, Jr. and other Niagen Bioscience executives is 10900 WILSHIRE BLVD, SUITE 600, LOS ANGELES, CA, 90024. Niagen Bioscience can also be reached via phone at (310) 388-6706 and via email at [email protected]. Learn More on Frank L. Jaksch, Jr.'s contact information.
Has Frank L. Jaksch, Jr. been buying or selling shares of Niagen Bioscience?: Frank L. Jaksch, Jr. has not been actively trading shares of Niagen Bioscience during the last quarter. Most recently, Frank L. Jaksch, Jr. sold 37,161 shares of the business's stock in a transaction on Friday, December 13th. The shares were sold at an average price of $6.19, for a transaction totalling $230,026.59. Following the completion of the sale, the director now directly owns 244,179 shares of the company's stock, valued at $1,511,468.01. Learn More on Frank L. Jaksch, Jr.'s trading history.
Who are Niagen Bioscience's active insiders?: Niagen Bioscience's insider roster includes Stephen Block (Director), Robert Fried (CEO), Frank Jaksch, Jr. (Director), Ozan Pamir (CFO), and Kristin Patrick (Director). Learn More on Niagen Bioscience's active insiders.
Are insiders buying or selling shares of Niagen Bioscience?: In the last twelve months, Niagen Bioscience insiders bought shares 2 times. They purchased a total of 6,685 shares worth more than $45,613.65. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 37,161 shares worth more than $230,026.59. The most recent insider tranaction occured on November, 14th when CFO Ozan Pamir bought 4,465 shares worth more than $30,406.65. Insiders at Niagen Bioscience own 9.4% of the company. Learn More about insider trades at Niagen Bioscience.
Information on this page was last updated on 11/14/2025.

Frank L. Jaksch, Jr. Insider Trading History at Niagen Bioscience

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/13/2024	Sell	37,161	$6.19	$230,026.59	244,179
6/12/2023	Buy	7,000	$1.69	$11,830.00	231,339
12/10/2020	Sell	37,829	$5.19	$196,332.51	262,168
5/16/2018	Buy	9,800	$3.59	$35,182.00
3/29/2018	Sell	474	$4.60	$2,180.40
3/27/2018	Sell	24,578	$4.60	$113,058.80
1/11/2018	Sell	28,379	$6.52	$185,031.08
12/21/2017	Sell	58,400	$6.19	$361,496.00
12/12/2016	Buy	2,000	$2.42	$4,840.00	201,557
9/1/2016	Buy	1,500	$3.32	$4,980.00	199,557

Frank L. Jaksch, Jr. Buying and Selling Activity at Niagen Bioscience

Niagen Bioscience Company Overview

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Today's Range

Now: $6.70

$6.51

$6.71

50 Day Range

MA: $7.28

$6.40

$9.90

2 Week Range

Now: $6.70

$5.16

$14.69

Volume

581,224 shs

Average Volume

833,772 shs

Market Capitalization

$534.73 million

P/E Ratio

27.92

Dividend Yield

N/A

Beta

2.31